GreyWolf Therapeutics is a drug discovery biotechnology company focusing on immuno-oncology. It develops immunotherapies that illuminate non-responsive tumors for destruction by the immune system. The company's aim is to change the neoantigen repertoire in cancer, increasing tumor visibility and extending the therapeutic benefit of immunotherapy.